Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

Ferring

Status: Completed

Conditions: Nocturia Associated With Nocturnal Polyuria

Treatments: Drug: desmopressin

Study type: Observational

Funder types: Industry

Identifiers

NCT00902265

FE992026 CS33

Details and patient eligibility

About

Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (Nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.

Enrollment: 138 patients

Sex: Male

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Therapeutic need according to Summary of Product Characteristics
• Written informed consent

Exclusion criteria

• Contraindications according to Summary of Product Characteristics

Trial design

138 participants in 1 patient group

desmopressin

Description:

Participants with benign prostate syndrome suffering from nocturia associated with nocturnal polyuria. Drug given by prescription.

Treatment:

Drug: desmopressin